Resilience Government Services, Inc.
Dba Nanotherapeutics Inc
CAGE Code: 3GQS9
NCAGE Code: 3GQS9
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 073438462
Summary
Resilience Government Services, Inc., Dba Nanotherapeutics Inc is an Active Manufacturer with the Cage Code 3GQS9 and is tracked by Dun & Bradstreet under DUNS Number 073438462..
Address
13200 Nw Nano Ct
Alachua FL 32615-8726
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Tucker-Davis Technologies, Inc. Wallace D E Construction Corp Heat Pipe Technology Inc Ellis Environmental Group, Llc Pharmatec Inc Helena Chemical Co Advanced Police Concepts, Llc Goldman Friedman Llc Ascend Advanced Therapies Group, Metagene Corp Contemporary Management Concepts Inc Florida Hosa Inc Suwannee River Area Health Education Daimonion Diagnostics Llc Tutogen Medical (United States) , Rts Laboratories Inc American Fire Hydrant Service Oxidative Stress Associates Inc Alonzo Perkins Inc Novabone Products Llc
Frequently Asked Questions (FAQ) for CAGE 3GQS9
- What is CAGE Code 3GQS9?
- 3GQS9 is the unique identifier used by NATO Organizations to reference the physical entity known as Resilience Government Services, Inc. Dba Nanotherapeutics Inc located at 13200 Nw Nano Ct, Alachua FL 32615-8726, United States.
- Who is CAGE Code 3GQS9?
- 3GQS9 refers to Resilience Government Services, Inc. Dba Nanotherapeutics Inc located at 13200 Nw Nano Ct, Alachua FL 32615-8726, United States.
- Where is CAGE Code 3GQS9 Located?
- CAGE Code 3GQS9 is located in Alachua, FL, USA.
Contracting History for CAGE 3GQS9 Most Recent 25 Records
- 75N93023F00001
- Development Of Lna14 Analytical Methods And Upstream And Downstream Processes For Manufacturing, And Scale-Up Manufacturing And Release Testing Of The Purified Lna14 Product
- 25 Aug 2023
- Development Of Lna14 Analytical Methods And Upstream And Downstream Processes For Manufacturing, And Scale-Up Manufacturing And Release Testing Of The Purified Lna14 Product
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $485,288.00
- Department Of Health And Human Services (Hhs)
- W911SR23F0057
- Clinical Development Phase 3 Study
- 1 Aug 2023
- Clinical Development Phase 3 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $2,326,036.74
- Department Of Defense (Dod)
- W911SR23F0057
- Clinical Development Phase 3 Study
- 3 Aug 2023
- Clinical Development Phase 3 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $4,502,407.33
- Department Of Defense (Dod)
- W911SR23F0057
- Clinical Development Phase 3 Study
- 23 Jun 2023
- Clinical Development Phase 3 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $2,326,036.74
- Department Of Defense (Dod)
- W911SR23F0057
- Drug Substance (Ds) Process Validation, Drug Product (Dp) Process Validation, Clinical Development Phase 3, And Storage/Stability For The Program With Ultimate Goal Of U.S. F.D.A. Licensure Of Bont Mab G03-52-01 Drug Product.
- 8 Mar 2023
- Drug Substance (Ds) Process Validation, Drug Product (Dp) Process Validation, Clinical Development Phase 3, And Storage/Stability For The Program With Ultimate Goal Of U.S. F.D.A. Licensure Of Bont Mab G03-52-01 Drug Product.
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $4,400,000.00
- Department Of Defense (Dod)
- W911SR23F0057
- Clinical Development Phase 3 Study
- 17 Aug 2023
- Clinical Development Phase 3 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $4,502,407.33
- Department Of Defense (Dod)
- W911SR22F0014
- Clinical Development Phase 2 Study
- 5 Jan 2022
- Clinical Development Phase 2 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $18,721,186.19
- Department Of Defense (Dod)
- W911SR22F0014
- Clinical Development Phase 2 Study
- 30 Nov 2022
- Clinical Development Phase 2 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $53,936,979.77
- Department Of Defense (Dod)
- W911SR22F0014
- Clinical Development Phase 2 Study
- 1 Aug 2022
- Clinical Development Phase 2 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $45,369,759.51
- Department Of Defense (Dod)
- W911SR22F0014
- Cgmp Ds Confirmation Run(S)
- 26 Jul 2023
- Cgmp Ds Confirmation Run(S)
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $83,988,904.63
- Department Of Defense (Dod)
- W911SR22F0073
- Ds Process Characterization
- 1 Aug 2023
- Ds Process Characterization
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $3,861,246.55
- Department Of Defense (Dod)
- W911SR22F0014
- Clinical Development Phase 2 Study
- 18 Apr 2022
- Clinical Development Phase 2 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $43,102,085.84
- Department Of Defense (Dod)
- W911SR22F0014
- Cgmp Ds Confirmation Run(S)
- 1 Aug 2023
- Cgmp Ds Confirmation Run(S)
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $86,818,904.63
- Department Of Defense (Dod)
- W911SR22F0073
- Ds Process Characterization
- 3 Aug 2023
- Ds Process Characterization
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $4,861,155.86
- Department Of Defense (Dod)
- W911SR22F0073
- Ds Process Characterization
- 28 Oct 2022
- Ds Process Characterization
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $2,417,521.55
- Department Of Defense (Dod)
- W911SR22F0014
- Cgmp Ds Confirmation Run(S)
- 29 Jun 2023
- Cgmp Ds Confirmation Run(S)
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $83,988,904.63
- Department Of Defense (Dod)
- W911SR22F0014
- Botmab Clinical Development Phase 2 Study
- 30 Jun 2022
- Botmab Clinical Development Phase 2 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $45,369,759.51
- Department Of Defense (Dod)
- W911SR22F0014
- Botmab Clinical Development Phase 2 Study
- 9 Mar 2023
- Botmab Clinical Development Phase 2 Study
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $76,253,307.63
- Department Of Defense (Dod)
- W911SR22F0014
- Incrementally Fund Program Management Clin 0001 And Clin 0003 Cgmp Ds Confirmation Run On Botmabs Project.
- 17 Feb 2023
- Incrementally Fund Program Management Clin 0001 And Clin 0003 Cgmp Ds Confirmation Run On Botmabs Project.
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $76,253,307.63
- Department Of Defense (Dod)
- W911SR22F0014
- Cgmp Ds Confirmation Run(S)
- 8 Aug 2023
- Cgmp Ds Confirmation Run(S)
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $86,818,904.63
- Department Of Defense (Dod)
- W911SR22F0014
- Cgmp Ds Confirmation Run(S)
- 12 Apr 2023
- Cgmp Ds Confirmation Run(S)
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $80,677,629.63
- Department Of Defense (Dod)
- W911SR22F0073
- Ds Process Characterization
- 7 Mar 2023
- Ds Process Characterization
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $4,417,521.55
- Department Of Defense (Dod)
- W911SR22F0014
- Cgmp Ds Confirmation Run(S)
- 28 Sep 2023
- Cgmp Ds Confirmation Run(S)
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $86,818,904.63
- Department Of Defense (Dod)
- W911SR22F0073
- Ds Process Characterization
- 16 Jun 2022
- Ds Process Characterization
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $2,417,521.55
- Department Of Defense (Dod)
- W911SR22D0009
- Acquisition Of Fda Approved Product
- 3 Jan 2022
- Acquisition Of Fda Approved Product
- W6qk Acc-Apg
- Department Of Defense (Dod)
- $0.00
- Department Of Defense (Dod)